Pfizer Beats Expectations in Q3 and Raises Its Guidance. Is the Stock Due for a Big Rally?

PFE posted a clean Q3 beat and raised full-year guidance, delivering $16.6B in revenue against a $15.9B forecast and $0.87 in EPS versus the $0.73 analysts expected. That is a 4.4% revenue surprise and a roughly 19% EPS surprise, a meaningful gap for a large-cap pharma name.

The company also flagged 32% growth from launched and acquired products. Interpretation: that figure suggests the post-COVID rebuild is gaining traction, since PFE has been fighting declining COVID-related revenues that helped drive the stock roughly 30% lower over five years.

Valuation is the other pillar of the bull case. PFE trades at about 10x forward earnings and carries a 5.6% dividend yield. Interpretation: at that multiple, a guidance raise paired with a double-digit EPS beat gives the market a reason to question whether the discount still fits, though a low multiple can also reflect lingering doubts about how fast COVID revenue keeps shrinking.

The raised guide matters most here. A beat alone can be a one-quarter event, but a higher full-year outlook signals management expects the strength to persist through year-end.